Avatrombopag-Daratumumab Combination Therapy

The combination of avatrombopag and daratumumab appears to be a treatment approach for chronic refractory immune thrombocytopenia (CRITP), particularly in pediatric patients. According to the search results, this combination has shown promising results in early clinical use. Avatrombopag (brand name Doptelet) is a thrombopoietin receptor agonist that stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in increased platelet production. It's an orally bioavailable small molecule that doesn't compete with thrombopoietin for binding to the TPO receptor and has an additive effect with TPO on platelet production. Avatrombopag is administered orally, typically starting at 20 mg once daily with food, with dose adjustments based on platelet count response. The maximum daily dose is 40 mg (2 tablets). Daratumumab (brand name Darzalex) is an IgG1k monoclonal antibody that targets CD38, a protein overexpressed in multiple myeloma cells. It works by binding to CD38, causing cells to undergo apoptosis via various mechanisms including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis. Daratumumab is administered intravenously at a doctor's office or hospital clinic. The combination of avatrombopag and daratumumab has been studied in children with chronic refractory immune thrombocytopenia (CRITP). According to a recent study, three pediatric patients (aged 5, 7, and 12 years) with CRITP who had previously failed multiple treatments showed rapid and durable responses to this combination therapy. The study reported that the time to response (defined as platelet count ≥30 × 10^9/L with at least a twofold increase in baseline count) ranged from 4 to 45 days, with complete responses (platelet count ≥100 × 10^9/L) achieved between 6 and 51 days. The sustained response lasted between 48 and 204 days during the follow-up period of 25.9 to 39.1 weeks. Importantly, the bleeding score decreased from grade 3 to grade 0 during follow-up, and no significant treatment-related adverse events were reported. The researchers concluded that the combination of daratumumab with avatrombopag may be a safe and efficacious therapy for children with CRITP, though they noted that further exploration is needed. This combination represents an innovative approach to treating refractory thrombocytopenia by targeting both increased platelet production (through avatrombopag) and potentially addressing the autoimmune component of the disease (through daratumumab's effects on CD38-expressing cells).